

NEWS RELEASE

IX BIOPHARMA TO PRESENT WAFERMINE PHASE 2 STUDY RESULTS AT THE BIO-EUROPE 24TH ANNUAL INTERNATIONAL PARTNERING CONFERENCE

Singapore, 5 November 2018 – Specialty pharmaceutical company **iX Biopharma Ltd** (“iX Biopharma” or “the Group”) will be presenting the positive results from the Phase 2 clinical KET010 study for **Wafermine**, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark. Dr Janakan Krishnarajah, iX Biopharma’s Chief Medical Officer, will be presenting the results on 6 November 2018 at 3:00pm (GMT+1).

Bio-Europe is Europe’s largest annual life science partnering conference. The conference facilitates new partnerships by allowing companies to present themselves and identify business and licensing opportunities. It is attended by approximately 2,000 companies and 4,000 business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts from all around the world.

The Bio-Europe conference gives iX Biopharma an opportunity and platform to identify suitable prospective partners for its range of products and the WaferiX sublingual delivery technology. Through the partnering program, iX Biopharma has received very strong interest for Wafermine and the WaferiX technology.

The presentation slides can be accessed at SGXNET and www.ixbiopharma.com starting from 9:00a.m. (GMT +8) on 7 November 2018.

About iX Biopharma Ltd

iX Biopharma is a Singapore public-listed specialty pharmaceutical and nutraceutical company, operating a fully integrated business model from drug development to laboratory testing, manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health conditions.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia.

The Group's nutraceuticals division, Entity Health Limited, recently launched its Entity line of nutraceutical products and is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. In addition to the successful registration of Wafesil and Silcap, the Group's nutraceutical arm, Entity Health, has also applied for assessment by TGA for quality and safety of its nutraceutical products. To date, the Group has successfully obtained 15 product listings on the ARTG with 8 listings for domestic sales and 7 listings for export sales on the ARTG.

Contact for media:

Dr Janakan Krishnarajah

Chief Medical Officer, iX Biopharma

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com

Eva Tan

Commercial Director, iX Biopharma

T: +65 6235 3212

E: eva.tan@ixbiopharma.com

This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), for compliance with the relevant rules of the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this document. This document has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document. The contact person for the Sponsor is Mr Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.